-+ 0.00%
-+ 0.00%
-+ 0.00%

Shandong Boan's BA1104 Meets Primary Endpoint in Phase 3 Cancer Trial in China

PUBT·11/17/2026 04:06:26
Listen to the news
Shandong Boan's BA1104 Meets Primary Endpoint in Phase 3 Cancer Trial in China
  • Shandong Boan Biotechnology disclosed Phase 3 results on Nov. 17, 2026, showing its nivolumab biosimilar BA1104 met the primary endpoint in China.
  • BA1104 matched Opdivo's efficacy when each was combined with chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.
  • Safety profiles were highly similar, with comparable immune responses to the two treatments.
  • A Chinese marketing application is due shortly, seeking the indications already authorized for Opdivo.
  • The FDA previously agreed that a single pharmacokinetic similarity study could support a US application without a Phase 3 trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261117-12415205), on November 17, 2026, and is solely responsible for the information contained therein.